Novo Ventures

Novo Ventures is the dedicated early-stage venture capital arm of Novo Holdings, a prominent international life science investor. As the holding company for the Novo Nordisk Foundation, Novo Holdings manages a substantial portfolio with a core mission to improve people's health and societal sustainability. This unique structure provides Novo Ventures with a long-term, purpose-driven investment philosophy, aligning its financial objectives with broader philanthropic goals in the life sciences sector.

The firm strategically focuses on innovative life science companies at the Seed, Series A, and Series B stages. Their investment scope is broad, encompassing critical areas such as biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health. Novo Ventures primarily targets promising ventures in North America and Europe, seeking companies with disruptive technologies and robust leadership.

Novo Ventures typically provides initial investments ranging from $5 million to $25 million, often taking a lead or significant co-investor position in funding rounds. Beyond financial capital, the firm offers substantial strategic guidance and operational support, leveraging the extensive network and deep industry expertise of Novo Holdings. This comprehensive support system aims to accelerate the development and commercialization of groundbreaking solutions.

The significant financial strength of Novo Holdings, which managed over $127 billion in assets as of December 2023, underpins Novo Ventures' capacity for substantial capital deployment and follow-on investments. This robust backing enables Novo Ventures to support its portfolio companies through various growth phases, fostering long-term partnerships dedicated to advancing life sciences and contributing to the Novo Nordisk Foundation's overarching mission.